CM
BIO icon

Capula Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Capula Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,287
Closed -$2M – 803
2025
Q2 		$2M Sell
8,287
-819
-9% -$194K 0.02% 136
2025
Q1 		$2.22M Buy
+9,106
New +$2.74M 0.01% 188
2023
Q3 		– Sell
-1,280
Closed -$485K – 517
2023
Q2 		$485K Buy
1,280
+730
+133% +$297K 0.01% 312
2023
Q1 		$263K Sell
550
-1,890
-77% -$885K ﹤0.01% 552
2022
Q4 		$1.03M Buy
2,440
+1,950
+398% +$787K 0.01% 406
2022
Q3 		$204K Buy
+490
New +$244K ﹤0.01% 583

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capula Management's BIO Position: Q3 2025 in Review

Capula Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2025, closing a stake of 8,287 shares — an estimated $2M sold.

Capula Management first reported a position in BIO in Q3 2022 and held it in 6 quarters. The position peaked at $2.22M in Q1 2025. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

  • Capula Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2025 after selling out during the quarter.
  • Capula Management sold 8,287 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $2M.
  • Capula Management first reported a position in Bio-Rad Laboratories Class A in Q3 2022 and held it in 6 quarters.
  • Capula Management's Bio-Rad Laboratories Class A position peaked at $2.22M in Q1 2025.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Capula Management's 13F filing for Q3 2025, filed 14 Nov 2025.